Is United Therapeutics Corporation (UTHR) a Buy, Sell, or Hold?
United Therapeutics Corporation
NASDAQ:UTHR
$526.66 USD
-$8.91 (-1.66%)
- Volume
- 372.63K
- Average Volume
- 486.46K
- Market Capitalization
- $22.35B
- P/E Ratio
- 17.99
- Dividend Yield
- 0.00%
- Price Target
- $625.00
- Year High
- $609.35
- Year Low
- $272.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.79
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Martine A. Rothblatt |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | UTHR |
| CUSIP | 91307C102 |
| CIK | 0001082554 |
| Web | https://www.unither.com |
| Phone | 301 608 9292 |
| Currency | USD |
| Employees | 1400 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.79 |
| Quick Ratio | 4.50 |
| Cash Ratio | 1.79 |
Sales & Book Value
| Annual Sales | $3.18B |
| Price / Sales | 7.05 |
| Cash Flow | 23.38 |
| Price / Cash Flow | 21.98 |
| Price / Book | 3.88 |
Price Target and Rating
| Average Stock Price Forecast | $625.00 |
| High Stock Price Forecast | $735.00 |
| Low Stock Price Forecast | $516.00 |
| Forecast Upside/Downside | -15.73% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 30 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $27.86 |
| Trailing P/E Ratio | 17.99 |
| PEG Ratio | 2.26 |
| P/E Growth | 2.26 |
| Net Income | $1.33B |
| Net Margin | 40.61% |
| Pretax Margin | 50.75% |
| Return on Equity | 19.24% |
| Return on Assets | 19.17% |
Financials Score
| AltmanZ Score | 20.01 |
| Piotroski Score | 6.00 |
| Working Capital | 2.27B |
| Total Assets | 6.71B |
| Ebit | 1.63B |
| Market Cap | 22.35B |
| Total Liabilities | 813.1M |
Poll Results
About United Therapeutics Corporation (NASDAQ:UTHR) Stock
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. U ... nituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
2026-07-09 15:30:27
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy
2026-07-06 18:45:27
United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from currently approved products, providing a strong commercial base. Ralinepag and Nebulized Tyvaso in IPF are near-term pipeline catalysts, with multi-billion dollar peak sales potential if approved.
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
2026-07-06 08:45:24
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
2026-07-03 09:55:17
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
United Therapeutics Corporation Acquires Thymmune Therapeutics
2026-07-02 06:30:00
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of th.
14 value stocks of companies primed for rapid growth through 2028
2026-07-01 12:10:00
Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.
2026-06-29 06:30:00
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure that enables donor lungs to be assessed outside the body after procurement and before transplantation. The PMA, submitted by United Therapeutics' wholly.
These 3 Stocks Lowered Their Share Counts Drastically in Q1
2026-06-09 09:35:45
While markets often view large-scale buyback authorizations as positives in and of themselves, authorizations are just one part of the buyback equation. Unlike dividends, which companies must pay after declaring, there is no hard requirement for companies to spend the buyback capacity they authorize.
Frequently Asked Questions
-
What is the current United Therapeutics Corporation (UTHR) stock price?
-
United Therapeutics Corporation(NASDAQ:UTHR) stock price is $526.66 in the last trading session. During the trading session, UTHR stock reached the peak price of $609.35 while $272.12 was the lowest point it dropped to. The percentage change in UTHR stock occurred in the recent session was --1.66% while the dollar amount for the price change in UTHR stock was -$-8.91.
-
UTHR's industry and sector of operation?
-
The NASDAQ listed UTHR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of UTHR?
-
Martine A. Rothblatt | Founder, Chairman & Chief Executive Officer
James C. Edgemond | Chief Financial Officer & Treasurer
Michael I. Benkowitz | President & Chief Operating Officer
Paul A. Mahon | Executive Vice President, General Counsel & Corporate Secretary
Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation -
How many employees does UTHR have?
-
Number of UTHR employees currently stands at 1400. UTHR operates from 1040 Spring Street, Silver Spring, MD 20910, US.
-
Link for UTHR official website?
-
Official Website of UTHR is: https://www.unither.com
-
How do I contact UTHR?
-
UTHR could be contacted at phone #301 608 9292 and can also be accessed through its website. UTHR operates from 1040 Spring Street, Silver Spring, MD 20910, US.
-
How many shares of UTHR are traded daily?
-
The average number of UTHR shares traded daily for last 3 months was 486.46K.
-
What is the market cap of UTHR currently?
-
The market value of UTHR currently stands at $22.35B with its latest stock price at $526.66